Feb 14, 2013, 02.09 PM | Source: Reuters
Shares in Dr Reddy's Laboratories fall 2.1 percent on worries the drug maker will post lower-than-expected October-December earnings, due later in the day
Margins are also expected to see significant erosion, several dealers add.
Dr Reddy's could miss consensus earnings per share (EPS) estimates by 6 percent in the October-December quarter, according to Thomson Reuters StarMine SmartEstimate data, which measures the forecasts from top-ranked analysts against wider forecasts. * StarMine SmartEstimate suggests EPS for the quarter ending December at Rs 26.03 compared with mean estimate of Rs 27.89.
Dr Reddys Labs stock price
On June 24, 2016, Dr Reddys Laboratories closed at Rs 3150.30, down Rs 20.4, or 0.64 percent. The 52-week high of the share was Rs 4382.95 and the 52-week low was Rs 2750.00.
The company's trailing 12-month (TTM) EPS was at Rs 79.39 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 39.68. The latest book value of the company is Rs 623.30 per share. At current value, the price-to-book value of the company is 5.05.
I won’t be surprised to see pharma as the story
CNBC-TV18's Ekta Batra lists out stocks that you s
Here are a few top buzzing midcap stocks picked by
However, it warns that first half of FY17 earnings
Sandeep Wagle of powermywealth.com recommends sell
Religare has recommended hold rating on Dr Reddys